The phrase “preventive care” has been so thoroughly absorbed into the vocabulary of public health that questioning any specific test or visit feels almost transgressive. Annual physicals, routine bloodwork, full-body scans, “executive physicals” sold by upscale clinics — all are wrapped in the implicit promise that more screening means better health. The evidence behind that promise, looked at carefully, is more mixed than most patients realize.
This is not an argument against prevention. It’s an argument for prevention that’s actually supported by data, and against prevention that isn’t.
What the USPSTF actually recommends
The U.S. Preventive Services Task Force is the most widely cited evidence-based body for screening recommendations. Its grading system rates services A through D plus “I” for insufficient evidence. A and B grades are services with net benefit; C and D are services where benefit is small or absent on average; I means the evidence doesn’t support a clear answer.
Many tests routinely offered or expected by patients sit at C, D, or I. Vitamin D screening in asymptomatic adults, EKGs in low-risk adults, and routine chest X-rays for lung cancer screening in non-smokers all fall outside the recommended-for-everyone category. The annual physical itself, as a structured ritual, has limited support in randomized trial data — it tends not to reduce mortality in adults at average risk.
Where overdiagnosis becomes the problem
The deeper issue is that screening tests can find things that look like disease but never would have caused harm. This is overdiagnosis, and it’s been documented most clearly in thyroid cancer, prostate cancer, and breast cancer screening. South Korea’s experience with mass thyroid ultrasound screening produced a roughly 15-fold increase in thyroid cancer diagnoses over about 20 years, with no corresponding decrease in thyroid cancer mortality — strong evidence that most of the new “cancers” weren’t ones that needed finding.
Each overdiagnosis carries downstream cost: biopsies, surgeries, radiation, lifelong surveillance, anxiety, and the financial toll of treatments for “cancers” that were never going to kill anyone. The harms aren’t theoretical. They show up in the data whenever screening intensity gets ahead of evidence.
What’s worth doing anyway
Plenty of preventive care is genuinely valuable. Blood pressure monitoring, colonoscopy or stool-based screening within recommended age ranges, lipid screening, smoking cessation support, age-appropriate cancer screening (mammography, cervical screening, lung CT in eligible smokers), vaccinations, and diabetes screening in higher-risk adults all have solid evidence behind them.
The pattern is that prevention with a clear, randomized-trial-supported mortality or morbidity benefit is worth doing on schedule. Prevention sold as comprehensive luxury — full-body MRIs, broad tumor marker panels, executive physical packages — is largely uncorroborated and frequently leads to false alarms and follow-up cascades.
The takeaway
Preventive care is not a uniformly virtuous category. Some of it saves lives. Some of it generates anxiety, cost, and harm without measurable benefit. The reasonable patient response is to ask which category any specific test falls into — and to be skeptical of clinics or marketing language that treat “more screening” as inherently better. The data doesn’t support that view, and acting on it costs real money and occasionally real organs.
Leave a Reply